Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn

被引:38
作者
Frazzoni, M
De Micheli, E
Zentilin, P
Savarino, V
机构
[1] Osped S Agostino, Div Med Interna & Gastroenterol, I-41100 Modena, Italy
[2] Univ Genoa, Dipartimento Med Interna & Special Med, Genoa, Italy
关键词
D O I
10.1111/j.1365-2036.2004.01998.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Patients with endoscopy-negative heartburn can be subdivided into non-erosive reflux disease and functional heartburn on the basis of abnormal and normal, respectively, oesophageal acid exposure. Different pathophysiological characteristics could explain the reportedly low efficacy of proton pump inhibitors in functional heartburn. Aim: To assess if non-erosive reflux disease and functional heartburn are pathophysiologically distinguishable. Methods: Oesophageal manometry and pH-monitoring were performed in 145 patients with endoscopy-negative heartburn, in 72 patients with erosive reflux disease, in 58 patients with complicated reflux disease, and in 60 controls. Results: Patients with non-erosive reflux disease (84 cases) and functional heartburn (61 cases) differed with regard to the prevalence of hiatal hernia (49% vs. 31%, P = 0.008), the mean lower oesophageal sphincter tone (18.5 vs. 28.4 mmHg, P < 0.05), and the number of upright diurnal acid refluxes lasting more than 5 min (3.6 vs. 0.37, P < 0.05). The results were very close in thenon-erosive reflux disease, erosive reflux disease and complicated reflux disease groups, whilst patients with functional heartburn were indistinguishable from controls. Conclusions: Pathophysiological characteristics typical of gastro-oesophageal reflux disease are found in patients with non-erosive reflux disease but not in patients with functional heartburn. This could explain the reportedly low efficacy of proton pump inhibitors in functional heartburn and suggests considering different management strategies.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 28 条
[1]  
*AM GASTR ASS, 1998, GASTROENTEROLOGY, V114, P579
[2]  
Bate CM, 1999, ALIMENT PHARM THERAP, V13, P59
[3]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[4]  
Clouse RE, 1999, GUT, V45, P31
[5]   An evidence-based appraisal of reflux disease management - the Genval workshop report [J].
Dent, J ;
Brun, J ;
Fendrick, AM ;
Fennerty, MB ;
Janssens, J ;
Kahrilas, PJ ;
Lauritsen, K ;
Reynolds, JC ;
Shaw, M ;
Talley, NJ .
GUT, 1999, 44 :S1-S16
[6]   Functional heartburn: the stimulus, the pain, and the brain [J].
Fass, R ;
Tougas, G .
GUT, 2002, 51 (06) :885-892
[7]   ARE ROUTINE DUODENAL AND ANTRAL BIOPSIES USEFUL IN THE MANAGEMENT OF FUNCTIONAL DYSPEPSIA - A DIAGNOSTIC AND THERAPEUTIC STUDY [J].
FRAZZONI, M ;
LONARDO, A ;
GRISENDI, A ;
DELLACASA, G ;
PULVIRENTI, M ;
FERRARI, AM ;
DIGREGORIO, C ;
MELINI, L .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1993, 17 (02) :101-108
[8]   Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease [J].
Frazzoni, M ;
De Micheli, E ;
Savarino, V .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (11-12) :1091-1098
[9]   Review article: transient lower oesophageal sphincter relaxations - a pharmacological target for gastro-oesophageal reflux disease? [J].
Hirsch, DP ;
Tytgat, GNJ ;
Boeckxstaens, GEE .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (01) :17-26
[10]  
Johnsson F, 1998, SCAND J GASTROENTERO, V33, P15